Lexaria Debt To Equity from 2010 to 2024

LEXX Stock  USD 2.13  0.02  0.93%   
Lexaria Bioscience Debt To Equity yearly trend continues to be fairly stable with very little volatility. Debt To Equity is likely to outpace its year average in 2024. Debt To Equity is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. View All Fundamentals
 
Debt To Equity  
First Reported
2010-12-31
Previous Quarter
0.7
Current Value
0.73
Quarterly Volatility
0.25655746
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lexaria Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexaria Bioscience's main balance sheet or income statement drivers, such as Depreciation And Amortization of 132.7 K, Interest Expense of 107.8 K or Other Operating Expenses of 8.2 M, as well as many indicators such as Price To Sales Ratio of 110, Dividend Yield of 0.0 or PTB Ratio of 57.61. Lexaria financial statements analysis is a perfect complement when working with Lexaria Bioscience Valuation or Volatility modules.
  
Check out the analysis of Lexaria Bioscience Correlation against competitors.

Latest Lexaria Bioscience's Debt To Equity Growth Pattern

Below is the plot of the Debt To Equity of Lexaria Bioscience Corp over the last few years. It is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. Lexaria Bioscience's Debt To Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lexaria Bioscience's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.01 %10 Years Trend
Slightly volatile
   Debt To Equity   
       Timeline  

Lexaria Debt To Equity Regression Statistics

Arithmetic Mean0.21
Geometric Mean0.06
Coefficient Of Variation123.83
Mean Deviation0.19
Median0.17
Standard Deviation0.26
Sample Variance0.07
Range0.7294
R-Value0.49
Mean Square Error0.05
R-Squared0.24
Significance0.07
Slope0.03
Total Sum of Squares0.92

Lexaria Debt To Equity History

2024 0.73
2023 0.7
2022 0.61
2021 0.005358
2020 5.97E-4
2016 0.0121

About Lexaria Bioscience Financial Statements

Lexaria Bioscience investors use historical fundamental indicators, such as Lexaria Bioscience's Debt To Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lexaria Bioscience. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Debt To Equity 0.70  0.73 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lexaria Stock Analysis

When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.